AstraZeneca and Amgen today announced that AMAGINE-2™, a pivotal, multi-arm Phase III trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12.
Latest from the network
Looking for something specific?
AstraZeneca and Amgen today announced that AMAGINE-2™, a pivotal, multi-arm Phase III trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12.
The joinery students proved they had business acumen as well as practical skills when their enterprise, the Charity Woodwork Company, using wood donated by AC Timber of Ely, proved a soaraway success at the Gazelle Colleges Market Maker competition.
Exceptionally this year, Cambridge International Academy will be holding 2 webi
Deloitte forecasts that in the first quarter of 2014, the installed base of compact tablets (8.5 inch or smaller screen) will surpass the base of classic tablets (9 inch and larger screen) for the first time.
That’s a key conclusion of the 2014 Cooper Lomaz Recruitment Salary Survey, widely respected throughout eastern England as a reliable barometer of employment and remuneration trends in the region.
Dates: 6 July to 11 July 2014
Location: Cambridge Judge Business School, Cambridge, UK »